Rekombinanter CCR4 (Mogamulizumab Biosimilar) Antikörper

Produktnummer ABIN7072382

Der Kaninchen Chimeric Anti-CCR4 (Mogamulizumab Biosimilar)-Antikörper wurde für Dep validiert. Er ist geeignet, CCR4 (Mogamulizumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter CCR4 (Mogamulizumab Biosimilar) Antikörper (ABIN7072382)

Target: CCR4 (Mogamulizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser CCR4 (Mogamulizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Depletion (Dep)

Klon: KW-0761

Produktdetails anti-CCR4 (Mogamulizumab Biosimilar) Antikörper

Verwendungszweck: Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa

Spezifität: This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: This antibody was prepared by humanization of a mouse anti-CCR4 mAb.

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu CCR4 (Mogamulizumab Biosimilar)

Target: CCR4 (Mogamulizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: CD194, CKR-4, CCR-4, CCR4, K5-5

UniProt: P51679